Early COPD Exacerbation Treatment with Combination of ICS and LABA for Patients Presenting with Mild-to-Moderate Worsening of Dyspnea

References

• Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27(1):188–207. PubMed PMID: 16387952.
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28(3):523–532. PubMed PMID: 16611654.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2):196–204. PubMed PMID: 3492164.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57(10):847–852. PubMed PMID: 12324669. Pubmed Central PMCID: 1746193.
   PubMed Web of Science ®Google Scholar
• Kanner RE, Anthonisen NR, Connett JE, Lung Health Study Research G. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164(3):358–364. PubMed PMID: 11500333.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007; 30(5):907–913. PubMed PMID: 17715163.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. AAch Intern Med 2003; 163(5):585–591. PubMed PMID: 12622605.
   PubMed Web of Science ®Google Scholar
• Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997; 156(6):1719–1724. PubMed PMID: 9412546.
   PubMed Web of Science ®Google Scholar
• Connors AF, Jr, Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154(4 Pt 1):959–967. PubMed PMID: 8887592.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59(5):387–395. PubMed PMID: 15115864. Pubmed Central PMCID: 1746989.
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW, Group GS. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58(7):589–593. PubMed PMID: 12832673. Pubmed Central PMCID: 1746751.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128–1138. PubMed PMID: 20843247.
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303(23):2359–2367. PubMed PMID: 20551406.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J 2007; 14 Suppl B:5B–32B. PubMed PMID: 17885691. Pubmed Central PMCID: 2806792.
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169(12):1298–1303. PubMed PMID: 14990395.
   PubMed Web of Science ®Google Scholar
• Bischoff EW, Hamd DH, Sedeno M, Benedetti A, Schermer TR, Bernard S, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66(1):26–31. PubMed PMID: 21037270.
   PubMed Web of Science ®Google Scholar
• Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-management education program including an action plan for acute COPD exacerbations. COPD 2009; 6(5):352–358. PubMed PMID: 19863364.
   PubMedGoogle Scholar
• Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3):375–407. PubMed PMID: 1382936.
   PubMed Web of Science ®Google Scholar
• Johansson SA, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982; 22(6):523–529. PubMed PMID: 7128664.
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39--47.
   Google Scholar
• Bourbeau J, Nault D, Sedeno M, et al. Content and images from the program Living Well with COPD (2nd Edition). 2005. Available from: www.livingwellwithcopd.com
   Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Jan 15;175(2):144–149. PubMed PMID: 17053207.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, et al. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013; 68(2):142–148. PubMed PMID: 23161645.
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150(1):11–16. PubMed PMID: 8025735.
   PubMed Web of Science ®Google Scholar
• McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. A Am J Respir Crit Care Med 1998; 157(3 Pt 1):704–709. PubMed PMID: 9517579.
   PubMed Web of Science ®Google Scholar
• Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355(9203):542–545. PubMed PMID: 10683005.
   PubMed Web of Science ®Google Scholar
• Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52(1):67–71. PubMed PMID: 9039248. Pubmed Central PMCID: 1758400.
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Brandolese R, Poggi R, Manzin E, Rossi A. Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intens Care Med 1990; 16(2):108–114. PubMed PMID: 2332537.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Califano C, Di Perna F, D'Amato M, Terzano C, Matera MG, et al. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Respir Med 2002; 96(10):790–795. PubMed PMID: 12412978.
   PubMed Web of Science ®Google Scholar
• Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro E, Matera MG, et al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2002; 24(4):595–604. PubMed PMID: 12017404.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther 2003;16(4):197–201. PubMed PMID: 12850121.
   PubMed Web of Science ®Google Scholar
• Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309(21):2223–2231. PubMed PMID: 23695200.
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29(4):660–667. PubMed PMID: 17251232.
   PubMed Web of Science ®Google Scholar
• Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165(5):698–703. PubMed PMID: 11874817.
   PubMed Web of Science ®Google Scholar
• Mirici A, Metal M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2003; 23(1):55–62. PubMed PMID: 23319094.
   PubMed Web of Science ®Google Scholar